Research records indexed for Liraglutide
This page carries 12 of the 5,673 records that the literature query returned for Liraglutide, selected by citation count and preferring records that name the compound in their title. It is a selection, not a complete index, and the 5,661 records it does not carry are not represented here. Every row resolves to a real identifier and names the study model, so no finding reads as a human claim by default. The compound page is Liraglutide.
Indexed records
| Record | Year | Study type | Model | n as stated | What it reported |
|---|---|---|---|---|---|
| Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial pmid:35015037 | 2022 | Clinical Trial, Phase III, research-article | human trial | Not stated | Indexed as clinical trial, phase iii, research-article. study model from MeSH "Humans" with publication type "clinical trial, phase iii". subject headings: Diabetes Mellitus; Obesity; Body Weight; Weight Loss; Placebos. |
| Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined pmid:33951361 | 2021 | Research Support, Non-U.S. Gov't, Randomized Controlled Trial | human trial | Not stated | Indexed as research support, non-u.s. gov't, randomized controlled trial. study model from MeSH "Humans" with publication type "randomized controlled trial". subject headings: Adipose Tissue; Obesity; Weight Loss; Anti-Obesity Agents; Body Size. |
| A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity pmid:32233338 | 2020 | Clinical Trial, Phase III, Research Support, Non-U.S. Gov't | human trial | Not stated | Indexed as clinical trial, phase iii, research support, non-u.s. gov't. study model from MeSH "Humans" with publication type "clinical trial, phase iii". subject headings: Gastrointestinal Diseases; Blood Glucose; Body Mass Index; Combined Modality Therapy; Injections, Subcutaneous. |
| Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10) pmid:31539622 | 2020 | Clinical Trial, Phase III, Comparative Study | human trial | Not stated | Indexed as clinical trial, phase iii, comparative study. study model from MeSH "Humans" with publication type "clinical trial, phase iii". subject headings: Diabetes Mellitus, Type 2; Metformin; Blood Glucose; Hypoglycemic Agents; Drug Therapy, Combination. |
| Endothelial GLP-1 (Glucagon-Like Peptide-1) Receptor Mediates Cardiovascular Protection by Liraglutide In Mice With Experimental Arterial Hypertension pmid:31747801 | 2020 | Research Support, Non-U.S. Gov't, research-article | rodent | Not stated | Indexed as research support, non-u.s. gov't, research-article. study model from MeSH "Mice, Inbred C57bl". subject headings: Cells, Cultured; Endothelial Cells; Mice, Inbred C57BL; Mice, Knockout; Hypertension. |
| Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial pmid:31186120 | 2019 | Clinical Trial, Phase III, Comparative Study | human trial | Not stated | Indexed as clinical trial, phase iii, comparative study. study model from MeSH "Humans" with publication type "clinical trial, phase iii". subject headings: Diabetes Mellitus, Type 2; Body Weight; Metformin; Administration, Oral; Injections, Subcutaneous. |
| Liraglutide in Children and Adolescents with Type 2 Diabetes pmid:31034184 | 2019 | Comparative Study, Research Support, Non-U.S. Gov't | human trial | Not stated | Indexed as comparative study, research support, non-u.s. gov't. study model from MeSH "Humans" with publication type "randomized controlled trial". subject headings: Gastrointestinal Diseases; Diabetes Mellitus, Type 2; Metformin; Insulin; Blood Glucose. |
| Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin: The Effect on Body Weight and Intrahepatic Lipid in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease pmid:30341767 | 2019 | Comparative Study, Research Support, Non-U.S. Gov't | human trial | Not stated | Indexed as comparative study, research support, non-u.s. gov't. study model from MeSH "Humans" with publication type "randomized controlled trial". subject headings: Diabetes Mellitus, Type 2; Body Weight; Metformin; Blood Glucose; Hypoglycemic Agents. |
| Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial pmid:30122305 | 2018 | Clinical Trial, Phase II, Comparative Study | human trial | Not stated | Indexed as clinical trial, phase ii, comparative study. study model from MeSH "Humans" with publication type "clinical trial, phase ii". subject headings: Obesity; Weight Loss; Blood Glucose; Placebos; Hypoglycemic Agents. |
| Liraglutide and Renal Outcomes in Type 2 Diabetes pmid:28854085 | 2017 | Comparative Study, Randomized Controlled Trial | human trial | Not stated | Indexed as comparative study, randomized controlled trial. study model from MeSH "Humans" with publication type "randomized controlled trial". subject headings: Diabetic Nephropathies; Kidney Failure, Chronic; Albuminuria; Diabetes Mellitus, Type 2; Creatinine. |
| 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial pmid:28237263 | 2017 | Comparative Study, Research Support, Non-U.S. Gov't | human trial | Not stated | Indexed as comparative study, research support, non-u.s. gov't. study model from MeSH "Humans" with publication type "randomized controlled trial". subject headings: Diabetes Mellitus, Type 2; Prediabetic State; Obesity; Body Weight; Weight Loss. |
| Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial pmid:27790809 | 2017 | Research Support, Non-U.S. Gov't, Multicenter Study | human trial | Not stated | Indexed as research support, non-u.s. gov't, multicenter study. study model from MeSH "Humans" with publication type "randomized controlled trial". subject headings: Atrial Fibrillation; Tachycardia, Ventricular; Diabetes Mellitus, Type 2; Chronic Disease; Disease Progression. |
Where this page sits
Compound page: Liraglutide. Class: Incretin receptor agonists.
Retrieved 2026-10-10.
Sources
- PubChem Compound Summary for CID 16134956, Liraglutide. PubChem, National Library of Medicine (2026). pubchem:16134956
- Drugs@FDA application register query for this compound, 11 application(s) returned: ANDA214568, ANDA217063, ANDA215421, NDA022341, ANDA217590. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:liraglutide
- Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet (2009). pmid:19515413
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med (2016). pmid:27295427
- Liraglutide and Renal Outcomes in Type 2 Diabetes. N Engl J Med (2017). pmid:28854085
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med (2015). pmid:26132939
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet (2016). pmid:26608256
- Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. BMJ (2024). pmid:38286487
- Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal Transduct Target Ther (2024). pmid:39289339
On each stated value was matched to the record cited for it. That is record matching, not an appraisal of the research. Compiled and checked by: Peptide Monographs editorial desk. No qualified clinical reviewer.